Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients
Carcinoma, Non-Small-Cell Lung|Mesothelioma
DRUG: LBH589
Pharmacokinetic (PK) parameters, first 10 days
Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs), day 10 through end of treatment|Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation, first 10 days, day 10 through end of treatment plus follow-up|Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation, day 10 through end of treatment
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients